AmoyDx® HRD Focus Panel

Decentralized HRD Testing Solutions

Homologous recombination deficiency (HRD) is present in approximately 50% of ovarian cancer tumors.[1] A positive HRD status has been shown to be predictive of response to PARPi therapy for advanced ovarian cancer.



Single Assay Solution to Detect All HRD Parameters

Making Complex NGS Testing Easy to HANDLE

Innovative NGS technology:
Halo-shape ANnealing and Defer-Ligation Enrichment (HANDLE)



- Turnaround time (TAT) from sample to report: within 3 days
- Easy workflow and low cost, as simple as PCR assay
- One-tube, hands-on time < 1 hour, total library construction time < 5 hours

High Concordance with FDA Approved Assay[2]

100% Positive Percent Agreement

80% Negative Percent Agreement

87.8% Overall Percent Agreement

1. Konstantinopoulos, Panagiotis A et al. "Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer." Cancer discovery vol. 5,11 (2015): 1137-54. doi:10.1158/2159-8290.CD-15-0714
2. Fumagalli C, Betella I, Ranghiero A, et al. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica. 2022;114(4):288-294. doi:10.32074/1591-951X-791.

Comprehensively Designed GSS Algorithm

The AmoyDx proprietary GSS algorithm is a machine learning-based model which assesses genomic instability by analyzing different types of copy number events across the genome.[3]

Length of Copy Number (LCN)	Type of Copy Number (TCN)	Site of Copy Number (SCN)	Number of Breakpoints (NB)
• Large (>15 Mb) • Middle (10–15 Mb) • Small (5–10 Mb)	• Loss of Heterozygosity (LOH) • Allele-specific CNV • Allele-balanced CNV	• Telomere • Centromer • Other	

Copy number events are counted only once, resulting in no information redundancy.

Genomic Scar Score = $SVM(\sum_{1}^{n} w(LCN,TCN,SCN,NB) * CNV(n))$

Longer PFS with PARPi Treatment for GSS-positive Group[3]



The study highlights the promising value of GSS in identifying patients who may respond favorably to PARPi treatment.

Decentralized ANDAS Server Enables Fast and Secure In-house Analysis

ANDAS: AmoyDx NGS Data Analysis System

- Pre-installed software
- Automatic analysis pipeline
- Regularly updated database
- Data security
- Local end-to-end solution

3. Yuan W, Ni J, Wen H, et al. Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability. BJOG. 2022;129 Suppl 2:14-22. doi:10.1111/1471-0528.17324.

E-mail: info@amoydiagnostics.com
Address: 2 Science Park Drive, Ascent #01-08, Singapore 118222

CE IVD

F250302